GW Pharmaceuticals plc has announced the initiation of a third Phase III Sativex® clinical trial in the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Further reading
Leave a Reply
You must be logged in to post a comment.